Max Healthcare Institute Q4 FY26 Results: PAT Rs 342 Cr
Updated: 22 May 2026 • 11:19 am
Posted by:
Max Healthcare Institute Q4 FY26 results were declared on May 21, 2026. The company reported PAT of Rs 342 crore for the quarter ended March 31, 2026, up 7.0% YoY compared to Rs 319 crore in Q4 FY25. Revenue from operations stood at Rs 2,143 crore, up 12.0% YoY. Results are on a Consolidated basis. Max Healthcare Institute is a Hospitals company listed on Indian stock exchanges.
Click Here – Get Free Investment Predictions
Max Healthcare Institute Q4 FY26 Financial Highlights
| Metric | Q4 FY26 (Rs Cr) | Q4 FY25 (Rs Cr) | YoY Change |
|---|---|---|---|
| Revenue | 2,143 | 1,910 | +12.0% |
| Gross Profit | Rs 483 crore | 411 | +17.0% |
| Net Profit | 342 | 319 | +7.0% |
| Basis | Consolidated | ||
Note: Max Healthcare Institute Q4 FY26 results declared May 21, 2026. Verify from BSE/NSE audited filings before investment decisions.
Max Healthcare Institute Q4 FY26 Performance Analysis
The Max Healthcare Institute Q4 FY26 results reflect the company’s operational performance in the January to March 2026 quarter. The company delivered steady performance in line with sector trends. Max Healthcare Institute operates in the Hospitals sector, which benefited from India’s GDP growth above 6.5% in FY26.
Revenue of Rs 2,143 crore reflects steady business conditions in the Hospitals sector.
Screen the best stocks on the Univest Screener.
Key Factors Driving Max Healthcare Institute Q4 FY26 Results
Revenue and Business Performance
Max Healthcare Institute Q4 FY26 revenue of Rs 2,143 crore was up 12.0% YoY. Revenue momentum reflects steady demand in the Hospitals business.
Profitability and Margins
the business PAT of Rs 342 crore up 7.0% YoY. Sustaining profitability while scaling revenues remains the key management priority.
India Macro Backdrop
The January to March 2026 quarter benefited from India’s GDP growth above 6.5%, government capital expenditure of Rs 11.21 lakh crore for FY27, and resilient domestic consumption. RBI’s accommodative stance supported credit and demand conditions. The Hospitals sector saw strong tailwinds during this period.
FY27 Outlook
Following the firm results, management commentary on FY27 revenue guidance, margin expansion roadmap, and capital allocation will be key investor watchpoints. The Hospitals sector continues to benefit from India’s long-term structural growth.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Frequently Asked Questions on the company
What is Max Healthcare Institute Q4 FY26 net profit?
Ans. Max Healthcare Institute Q4 FY26 PAT of Rs 342 crore, up 7.0% YoY from Rs 319 crore in Q4 FY25. Results declared May 21, 2026, on a Consolidated basis.
What is Max Healthcare Institute Q4 FY26 revenue?
Ans. Max Healthcare Institute Q4 FY26 revenue from operations was Rs 2,143 crore, up 12.0% YoY. Verify from BSE/NSE filings.
When were Max Healthcare Institute Q4 FY26 results declared?
Ans. Max Healthcare Institute Q4 FY26 results were declared on May 21, 2026, at the board of directors meeting approving audited Q4 and FY26 financial statements.
Is Max Healthcare Institute a good investment after Q4 FY26?
Ans. Investment decisions require individual assessment of fundamentals, valuation, and risk. This article is for educational purposes only. Consult a SEBI-registered financial advisor before investing.
Recent Articles
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
FSN E-Commerce Ventures Nykaa Q4 FY26 Results: PAT Rs 41 Cr
Rashtriya Chemicals and Fertilisers Q4 FY26 Results: PAT Rs 189 Cr
Century Enka Q4 FY26 Results: PAT Rs 40 Cr
Ambalal Sarabhai Enterprises Q4 FY26 Results: PAT Rs 6 Cr
E to E Transportation Infrastructure Q4 FY26 Results: PAT Rs 24 Cr
Popular this week
FSN E-Commerce Ventures Nykaa Q4 FY26 Results: PAT Rs 41 Cr
Rashtriya Chemicals and Fertilisers Q4 FY26 Results: PAT Rs 189 Cr
Century Enka Q4 FY26 Results: PAT Rs 40 Cr
Ambalal Sarabhai Enterprises Q4 FY26 Results: PAT Rs 6 Cr
E to E Transportation Infrastructure Q4 FY26 Results: PAT Rs 24 Cr
Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
.webp){kind=small}